#United States #Fremont #cancer detection #Ultima Genomics #ppmSeq

Ultima Genomics Unveils ppmSeq™ Technology

Ultima Genomics has made a significant breakthrough in genomic sequencing with their latest innovation, ppmSeq™. This advanced technology delivers an unmatched combination of sensitivity and efficiency, particularly in the detection of minimal residual disease (MRD). A new publication available on bioRxiv highlights the remarkable capabilities of ppmSeq™, revealing its power to detect circulating tumor DNA (ctDNA) at levels as low as one-in-ten million (10^-7). This level of detection extends far beyond the capabilities of currently available clinical MRD assays.

Key Features of ppmSeq™ Technology

1. Enhanced Sensitivity: The research led by experts from Weill Cornell Medicine and the New York Genome Center highlights that ppmSeq can detect single-nucleotide variants (SNVs) with an error rate down to 8 x 10^-8. This exceptional accuracy is crucial for clinical applications, aiming for precise mutation identification in the context of MRD detection.

2. Superior DNA Recovery: Unlike traditional sequencing technologies, which require extensive sequencing efforts, the ppmSeq workflow dramatically reduces the sequencing requirements by 10 to 100-fold. This optimization facilitates a cost-effective whole-genome sequencing (WGS) approach while ensuring high sensitivity.

3. Streamlined Workflow: The simplicity of the whole-genome sequencing workflow contributes to its high efficiency. The assay yields over 20x coverage per nanogram of cell-free DNA (cfDNA), requiring significantly less input material for MRD detection and other applications.

4. Tumor-Informed and Tumor-Naive Applications: Notably, ppmSeq is beneficial in both tumor-informed MRD settings and in scenarios where matched tumor tissue is unavailable, thus expanding its utility in cancer monitoring.

Clinical Implications

The implications of ppmSeq technology extend into various clinical settings. By providing ultrasensitive detection capabilities, ppmSeq enables healthcare professionals to monitor disease progression more effectively, particularly in cancer patients. Key findings from recent studies demonstrate that ppmSeq can identify ctDNA patterns indicative of residual disease across numerous cancers, as well as offering ctDNA detection capabilities in the absence of previous tumor data.

Expert Insights

Dan A. Landau, MD, PhD, a prominent researcher in the field, remarked on the technology's potential, stating, "With its unique combination of low-cost and high accuracy, ppmSeq marks a real breakthrough in sequencing technology." The advantages of this technology could bring about new opportunities in cancer genetics, paving the way for timely interventions and better patient outcomes.

Future of Genomic Sequencing

As the demand for genomic information continues to escalate, Ultima Genomics aims to provide solutions that do not compromise on quality or cost. The company’s commitment to pushing the boundaries of sequencing technology is rooted in its purpose of unleashing the power of genomics at scale. By making high-quality genomic data more accessible, they hope to facilitate unprecedented advancements in clinical applications.

The full details of this study titled "Paired plus-minus sequencing is an ultra-high throughput and accurate method for dual strand sequencing of DNA molecules" can be accessed on bioRxiv, marking a crucial step toward enhanced precision in detecting minimal residual disease. As ppmSeq technology undergoes further validation, it promises to transform how clinicians manage cancer treatment and monitoring, ultimately leading to improved patient care and outcomes.

About Ultima Genomics

Ultima Genomics is a pioneering company focused on revolutionizing genomic sequencing. Their innovative approaches and commitment to cost-effective solutions are set to significantly impact research and clinical settings alike. To learn more about their initiatives and technology, visit Ultima Genomics.